通过孟德尔随机化识别心肌梗塞的潜在药物标
1Department of Endocrinology, Shaanxi Provincial People's Hospital, Xi'an, P. R. China.
PloS one
|December 23, 2024
概括
这项研究确定了与心肌梗塞 (MI) 风险相关的关键血和脑脊液蛋白. 研究结果揭示了像CD8A和DPEP1这样的潜在生物标志物,以改善对MI的理解和临床策略.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 心血管疾病研究研究
背景情况:
- 研究了血和脑脊液 (CSF) 蛋白质与心肌梗塞 (MI) 风险之间的联系.
- 突出了蛋白质生物标志物的潜力,以了解MI机制并告知临床实践.
研究的目的:
- 为了确定与心肌梗塞 (MI) 风险因果相关的特定血和CSF蛋白质.
- 探索血与CSF蛋白在MI病变发生过程中的不同作用.
主要方法:
- 使用的蛋白质定量特征位点 (pQTL) 数据和全基因组关联研究 (GWAS) 的综合统计数据用于MI.
- 采用孟德尔随机化 (MR),贝叶斯定位和斯皮尔曼相关性分析来评估因果关系.
- 专注于与血和CSF蛋白相关的cis作用单核酸多态 (SNP).
主要成果:
- 在血中鉴定出CD8A和HDHD2作为对MI的保护;在血中DPEP1与风险增加有关.
- 在CSF中发现CD30连接体,与心脏病发作风险有关.
- 通过贝叶斯协同定位确认了CD8A关联;没有注意到血和CSF发现之间的显著相关性.
结论:
- 几个血和CSF蛋白与心脏病发作风险有关,提供了新的生物学见解.
- 这些蛋白质生物标志物可以指导未来的研究,并有助于加强心肌梗塞预防和治疗策略.
更多相关视频
04:29A Modified Simple Method for Induction of Myocardial Infarction in Mice
Published on: December 3, 2021
3.5K
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.3K
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
